Abstract 147P
Background
In resectable esophageal squamous cell carcinoma (ESCC), there is limited evidence of the efficacy of serplulimab in combination with chemotherapy followed by minimally invasive esophagectomy. Therefore, we aimed to observe and evaluate its efficacy and safety in locally advanced ESCC.
Methods
Patients aged 18-75 years and classified as stage II-IVA according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual, who were histologically or cytologically diagnosed with ESCC, were deemed eligible to participate in this trial. Patients received 3 cycles of neoadjuvant therapy with serplulimab (4.5mg/kg intravenously on day 1), carboplatin (AUC=5 intravenously on day 1), albumin paclitaxel (260 mg/m2 intravenously on day 1); each cycle was repeated every 21 days. Surgery occurred 4-6 weeks after the last neoadjuvant treatment cycle. The primary outcome was the pathological complete response (PCR) rate of the tumour and lymph nodes. This prospective, single-arm, phase 2 trial was conducted at the Second Affiliated Hospital of Zhejiang University in China.
Results
A total of 48 patients were enrolled in this study, with no observed disease progression during the neoadjuvant treatment phase. The disease control rate and objective response rate were 100.0% and 68.8%, respectively. Most of the adverse events were grade 1-2, 2 (4.2%) patients experienced grade 3 adverse events. Three patients refused to receive surgical treatment and declined to participate in the study. Consequently, 45 patients received minimally invasive esophagectomy. All 45 patients achieved R0 resection, with 14 patients (31.1%) attaining a PCR for both the tumour and lymph nodes.
Conclusions
The administration of serplulimab in conjunction with chemotherapy in the neoadjuvant setting for locally advanced ESCC has demonstrated promising antitumor activity and an acceptable safety profile in this single-arm study. Extended follow-up to assess survival outcomes and a phase 3 randomized trial are necessary to further evaluate the efficacy and safety of the proposed treatment regimen.
Clinical trial identification
NCT05659251.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract